Acrux should now be looked at as another biotech.
Except it's still making money from it's products, it's cashflow positive and has plenty of money in the bank!
Even if royalties from Axiron half, they are still bringing in a decent amount of cash to push forward their new products
They also have the European market with the eostregen product, which could surprise.
Allan Gray's mandate probably doesn't allow them to invest in biotech companies, and that is probably why they are forced to sell. I'd be waiting for that announcement (ceasing to be substantial shareholder) and I'd be jumping in!
This stock could even get to cash backing if it hits low 20s
Add to My Watchlist
What is My Watchlist?
